Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,561 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Comparator: A Clear all
Completed Not applicable Interventional Results available

RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

NCT05965752
View directory record Official record
Conditions
Long COVID, Long COVID-19, Long COVID19
Interventions
BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham
Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions

NCT00865943
View directory record Official record
Conditions
Healthy
Interventions
Citalopram HBr eq. 10 mg tablets, single dose, CELEXATM 10 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study of AP0302 5% Versus a Vehicle Comparator

NCT02324985
View directory record Official record
Conditions
Pain, Delayed Onset Muscle Soreness
Interventions
S-Ibuprofen Topical Gel 5%, Vehicle Topical Gel
Drug
Lead sponsor
Aponia Laboratories, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Sep 27, 2026, 5:23 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07450547
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
ANG003 Dose A, ANG003 Dose B, Creon
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

NCT06088043
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
TAK-279, Placebo, Apremilast
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Green Light Therapy on Body Contouring and Cellulite

NCT03647748
View directory record Official record
Conditions
Fat Reduction
Interventions
Sham Comparator
Device
Lead sponsor
Ward Photonics LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Cape Coral, Florida • Cocoa Beach, Florida • Lake Mary, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

NCT03564158
View directory record Official record
Conditions
Healthy
Interventions
meropenem-vaborbactam, Placebo, Moxifloxacin
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Sub-Acute Stroke Rehabilitation With AMES

NCT00609115
View directory record Official record
Conditions
Cerebrovascular Stroke
Interventions
AMES device (test), AMES device (sham), AMES device (crossover)
Device
Lead sponsor
AMES Technology
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Rancho Mirage, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA + DHA in a SMEDS Formulation

NCT03443076
View directory record Official record
Conditions
Bioavailability
Interventions
EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved)
Dietary Supplement · Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Boca Raton, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Articulated Oral Airway as an Aid to Mask Ventilation

NCT03144089
View directory record Official record
Conditions
Mask Ventilation, Airway Obstruction Upper, Airway Management
Interventions
Articulated Oral Airway, Guedel oral airway (active comparator)
Device
Lead sponsor
Ron Abrons
Other
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

NCT00998218
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 27, 2026, 5:23 PM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

NCT05777759
View directory record Official record
Conditions
Chin Augmentation, Chin Retrusion
Interventions
Restylane Lyft with Lidocaine, Juvederm Voluma XC
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Manhattan Beach, California • Westport, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

NCT03098823
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Erythematosus, Fatigue
Interventions
RAYOS, Prednisone
Drug
Lead sponsor
Ampel BioSolutions, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
21
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

NCT00843713
View directory record Official record
Conditions
HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions
raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

NCT02484690
View directory record Official record
Conditions
Choroidal Neovascularization
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
52
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

NCT01850524
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Placebo, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Analgesic Value of Adductor Canal vs Femoral Block After Total Knee Arthroplasty

NCT03395990
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Active comparator: chloroprocaine, Sham comparator: saline
Procedure
Lead sponsor
Duke University
Other
Eligibility
56 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 27, 2026, 5:23 PM EDT
Not yet recruiting Not applicable Interventional

Home-Based Lower-Extremity Heat Therapy for Walking Function in Peripheral Artery Disease

NCT07653243
View directory record Official record
Conditions
PAD, PAD - Peripheral Arterial Disease
Interventions
Lower-Extremity Heat Therapy, Sham Lower-Extremity Heat Therapy
Device
Lead sponsor
Aquilo Sports, LLC
Industry
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Active, not recruiting Phase 3 Interventional

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Bomedemstat, Hydroxyurea, Bomedemstat placebo, Hydroxyurea placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Glendale, Arizona • Glendale, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869
View directory record Official record
Conditions
CMV Disease
Interventions
Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

NCT06037668
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
BVR-100, BES-100
Device
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Orlando, Florida • Boston, Massachusetts • Saint Charles, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 27, 2026, 5:23 PM EDT